Atrial fibrillation is the commonest sustained disBirmingham, 6 ischaemic heart disease was the commonest associated factor, which was followed order of cardiac rhythm. The presence of this arrhythmia confers a substantial increase in morclosely by hypertension. Whilst there is very limited data on the clinical epidemiology of atrial fibrilbidity and mortality, from heart failure, stroke and thromboembolism. This is particularly relevant with lation in non-Caucasian groups, the study by Zarifis a population which is generally getting more eldet al 6 in a multi-racial hospital population in erly. Therefore, more information on the clinical Birmingham found that in black or Afro-Caribbean epidemiology, appropriate management and patients the commonest underlying medical conimprovement of strategies to reduce stroke and dition was hypertension, and in South Asians, thromboembolic risks are needed. This is partiischaemic heart disease. This is in contrast to a cularly important in view of studies from large ranstudy of atrial fibrillation amongst Hong Kong Chidomised trials establishing the value of prophylactic nese, 7 where atrial fibrillation was frequently assoantithrombotic therapy in reducing strokes in atrciated with hypertension (29%), atherosclerotic vasial fibrillation. 1 cular disease (25%), and rheumatic heart disease Another common cardiovascular disorder leading (18%). In a survey of patients with known, treated to heart failure, stroke and thromboembolism is atrial fibrillation in two general practices in hypertension. Not surprisingly both atrial fibrilBirmingham, we found that hypertension was the lation and hypertension appear to be connected. In commonest underlying aetiological factor amongst the Framingham study, for example, hypertension 111 patients with atrial fibrillation; 8 however, only was considered to be the commonest cause of atrial a third of patients had ever presented to hospital, fibrillation, being present in over 50% of subjects. 2 suggesting that hospital surveys on clinical features In fact, hypertension was associated with a relative of patients with atrial fibrillation were unrepresentrisk of 1.9 for developing atrial fibrillation in the ative of the general population as a whole. UnfortuFramingham study. 2 In the Manitoba Follow-up nately, there is a distinct lack of epidemiological Study, hypertension was also common (53% cases) studies of the same nature as Framingham which and was associated with a relative risk of 1.42. 3 In have been reliably conducted in the UK, and prethe latter study either hypertension or ischaemic vious attempts at screening for atrial fibrillation in heart disease preceded atrial fibrillation in 65% of Britian have encountered low response rates. cases, suggesting that both hypertension and Why do patients with hypertension develop atrial ischaemic heart disease accounted for a large profibrillation? It is well recognised that patients with portion of cases of atrial fibrillation. chronic hypertension, particularly those with assoThe picture seems different, however, in studies ciated left ventricular hypertrophy, develop left atrfrom the UK. Nevertheless studies of the clinical ial dilatation. The latter does alter the electrophysiepidemiology of atrial fibrillation from Britain are ological properties of the atrium resulting in the limited, and some of the early studies have been propensity to developing atrial fibrillation. Patients criticised for studying small, selected elderly popuwith hypertension also develop significant diastolic lations which are unrepresentative of the general dysfunction and the concomitant increase in left population as a whole. 4 Some recent data are availatrial pressure is another predisposing factor. able from hospital and general practice surveys. For Finally, patients with hypertension are more prone example, in a study of acute hospital admissions to developing coronary artery disease, which is with atrial fibrillation from Glasgow ial fibrillation.
In this issue of the Journal of Human Hypertenmaximum effect only after 4 -6 h; by contrast, an intravenous loading dose of 0.75-1 mg digoxin gives sion, Kowey et al 9 provide a detailed review of atrial fibrillation and its management, with a North Amerlabile initial plasma digoxin levels (as high as 95 ng/ml, which may be potentially more dangerican perspective. They discuss the role of hypertension, current strategies in drug and non-pharmacoous. 15 Thus, loading still takes several hours to have its maximum effect in slowing the rate and caution logical treatment, anticoagulation and cardioversion, and possible future developments. Why is necessary in elderly patients or those with renal impairment. should hypertensionologists be interested in the clinical implications of having hypertension and Another underrecognised area in the management of atrial fibrillation in hypertensive patients is conassociated atrial fibrillation? Both conditions individually lead to an increased risk of stroke and comitant diastolic dysfunction.
16
Patients with hypertension and left ventricular hypertrophy often thromboembolism; in fact, the available data suggests that the presence of hypertension is an addihave stiff, non-compliant left ventricles, where systolic function remains preserved and abnormalities tive risk factor (by three-to five-fold) to atrial fibrillation for developing strokes. 2, 10 Data from the Atrial are in diastole. Patients who are initially in sinus rhythm and subsequently develop atrial fibrillation Fibrillation Investigators meta-analysis also suggested the presence of hypertension increases the lose their atrial transport, and if severe diastolic dysfunction is present, this may result in acute pulmonrisk of stroke two-fold. 10 In the Stroke Prevention in Atrial Fibrillation (SPAF) Study, the echocardioary oedema. However, the management of diastolic dysfunction, in contradistinction to the management graphic substudy suggested that left ventricular hypertrophy was an added risk for stroke in atrial of heart failure secondary to systolic dysfunction, remains illusive. 16, 17 Most of the drugs for systolic fibrillation on univariate analysis, but on multivariate analysis, only the presence of left atrial diladysfunction do not necessarily work as well in patients with diastolic dysfunction. By contrast, tation and left ventricular dysfunction emerged as independent risk factors. 11 The presence of a predrugs such as the calcium antagonists and betablockers have some effects due to the bradycardiac vious history of hypertension in patients with atrial fibrillation also merits consideration for anticoaguland lusitrophic properties that improve left ventricular filling. 16 The ACE inhibitors may also be ation. 12 However, patients with uncontrolled hypertension require control of blood pressure (BP) before useful by regressing left ventricular hypertrophy, but the use of digoxin in patients with diastolic dysinitiation of anticoagulation to avoid the risk of cerebral haemorrhage, since there is an association function may actually be detrimental. If the patient is in atrial fibrillation, this also crebetween uncontrolled BP and this adverse effect of warfarin therapy. 10, 13 ates a problem for an easy, non-invasive diagnosis of diastolic dysfunction. 17 The commonest nonKowey et al 9 also provide an insight into rational prescribing for patients with atrial fibrillation and invasive method of diagnosing the latter is by measuring the mitral inflow pattern on Doppler echocarhypertension. The presence of both conditions opens the possibility of using drugs, such as the diography. The presence of a reversed E to A ratio of the mitral inflow pattern is suggestive, although beta-blockers and calcium antagonists (such as verapamil and diltiazem), which have good ventricular not diagnostic of diastolic dysfunction-this parameter had certain caveats as it is altered by age, rate control effects in atrial fibrillation, as well as BP lowering. This may avoid concomitant use of mulheart rate, drugs and underlying disease. In the presence of atrial fibrillation, the A wave is lost which tiple drugs to individually control BP and ventricular rate in patients with atrial fibrillation.
makes it less easy to diagnose diastolic dysfunction without relying on other parameters such as the isoUnfortunately in many parts of the world, digoxin still remains the most common drug use for atrial volumetric relaxation time and the deceleration time. fibrillation, in both acute and chronic stages. [5] [6] [7] [8] Whilst digoxin is useful for controlling the resting Where do we go from here? More information on the clinical epidemiology of atrial fibrillation is heart rate in atrial fibrillation, it is less useful in exercise and conditions of high sympathetic drive. required; this includes vigilance and audit of current practices for screening and detecting atrial fibDigoxin is also ineffective in cardioversion or in paroxysmal atrial fibrillation. There is therefore a viewrillation in our clinical practice. Hypertension should be detected and treated, at least avoiding one point, especially in North America, that digoxin is 'a drug whose time has gone'.
14 One example of risk factor for developing atrial fibrillation, which also contributes towards the risk of stroke in this management differences, is in acute onset fast atrial fibrillation, where urgent rate control in North condition. We also need to develop safe antiarrhythmic strategies which are devoid of adverse America is commonly with beta-blockers (such as intravenous esmolol or metoprolol) or with calcium events, including proarrhythmia and other side effects. With the established benefits of antithromantagonists (such as intravenous verapamil or diltiazem). By contrast, in the UK, we still seem to botic therapy in preventing stroke and thromboembolism in atrial fibrillation we do need safe, rely on intravenous digoxin. 6 Although intravenous digoxin does begin to work sooner (Ͻ30 min) than effective, reliable and convenient methods of administrating antithrombotic therapy, including risk oral digoxin (approximately 30-60 min, or more), it does not work instantaneously. In fact, oral digistratification of these patients. We perhaps need to consider new antithrombotic regimes such as ticloptalisation with a loading dose of 1 mg produces peak blood levels of Ͼ1 ng/ml within 1-5 h and a idine, clopidogrel or their combinations with aspirin consideration of appropriate drug and antithrom-
